U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan’s dry eye franchise Restasis.
The Food and Drug Administration (FDA) has approved Restasis for treating chronic dry eye in adults and children ages 16 years and older. It’s available in single-use vials and a multiuse bottle.
Inspire has stopped co-promoting Restasis, the dry-eye drug launched by Allergan, according to the Triangle Business Journal. Inspire will still receive royalties on the drug at the same rate as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results